Nov 11, 2022 / 10:00AM GMT
Operator
Welcome to the Isofol Medical Q3 2022 presentation. Afterwards, there will be a question-and-answer session. (Operator Instructions) Today, I'm pleased to present CEO Ulf Jungnelius; and CFO Gustaf Albèrt. Please begin your meeting.
Ulf Jungnelius - Isofol Medical AB(publ)-CEO
Thank you so much and welcome to our presentation of the third-quarter results of this year. We are at the, we told you before, closing down the AGENT study in accordance with the ethical and regulatory requirements.
If we go to the next slide, the disclaimer, please read it through while I go to slide number 4. And slide number 4 starts with Q3 highlights. So let's look at what happened during the third quarter of this year.
First of all, in early August, we presented the data from our randomized pivotal Phase 3 study. And unfortunately and sadly, it showed that we did not achieve the primary endpoint of overall response rate or the key secondary endpoint of progression-free survival. Two endpoints there were required for a positive
Q3 2022 Isofol Medical AB (publ) Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot